Historically, medical treatment of acromegaly has mainly been used as an adjuvant therapy after surgery. In the last decades, an increased range of medical therapy options has been available. Somatostatin analogues have become the cornerstones of medical treatment in acromegaly and are even seen as a primary treatment in a selected group of acromegaly patients. The most recent medical treatment available for acromegaly patients is pegvisomant, a growth hormone receptor antagonist. To date, it is the most effective medical treatment, but it is costly. Pegvisomant is used as monotherapy and combined with somatostatin analogues. In this article, we review clinical studies and cohorts that have documented the efficacy of pegvisomant monotherapy and combined therapy and give a concise overview of associated side effects.

Keywords:
Combination therapy, Long-acting somatostatin analogues, Side effects, Monotherapy, Quality of life, Pegvisomant, Acromegaly
1.
Melmed S: Medical progress: acromegaly. N Engl J Med 2006;355:2558-2573.
2.
Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP: Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008;93:61-67.
3.
Holdaway IM, Bolland MJ, Gamble GD: A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008;159:89-95.
4.
Neggers SJ, Franck SE, de Rooij FW, Dallenga AH, Poublon RM, Feelders RA, et al: Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogues in acromegaly. J Clin Endocrinol Metab 2014;99:3644-3652.
5.
Neggers SJ, van der Lely AJ: Somatostatin analog and pegvisomant combination therapy for acromegaly. Nat Rev Endocrinol 2009;5:546-552.
6.
Neggers SJ, van der Lely AJ: Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm IGF Res 2011;21:129-133.
7.
Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ: Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002;23:623-646.
8.
Giustina A, Ambrosio MR, Beck Peccoz P, Bogazzi F, Cannavo S, De Marinis L, et al: Use of pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest 2014;37:1017-1030.
9.
Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342:1171-1177.
10.
van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-1759.
11.
Brue T, Castinetti F, Lundgren F, Koltowska-Haggström M, Petrossians P; ACROSTUDY Investigators: Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. Eur J Endocrinol 2009;161(suppl 1):S11-S17.
12.
Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brubach K, et al: The German ACROSTUDY: past and present. Eur J Endocrinol 2009;161(suppl 1):S3-S10.
13.
Sesmilo G, Resmini E, Bernabeu I, Aller J, Soto A, Mora M, et al: Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study. Clin Endocrinol (Oxf) 2014;81:883-890.
14.
Trainer PJ: ACROSTUDY: the first 5 years. Eur J Endocrinol 2009;161(suppl 1):S19-S24.
15.
van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, et al: Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012;97:1589-1597.
16.
Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, et al: Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007;156:75-82.
17.
Gutierrez LP, Koltowska-Haggstrom M, Jonsson PJ, Mattsson AF, Svensson D, Westberg B, et al: Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol Drug Saf 2008;17:90-102.
18.
Clemmons DR: Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 2011;57:555-559.
19.
van der Lely AJ, Bernabeu I, Cap J, Caron P, Colao A, Marek J, et al: Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 2011;164:325-333.
20.
Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, et al: Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005;365:1644-1646.
21.
Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ: Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 2009;160:529-533.
22.
Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ: Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 2007;92:4598-4601.
23.
Neggers SJ, de Herder WW, Feelders RA, van der Lely AJ: Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary 2011;14:253-258.
24.
Trainer PJ, Ezzat S, D'Souza GA, Layton G, Strasburger CJ: A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 2009;71:549-557.
25.
Droste M, Domberg J, Buchfelder M, Mann K, Schwanke A, Stalla G, et al: Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Eur J Endocrinol 2014;171:59-68.
26.
Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C, et al: Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005;90:5627-5631.
27.
van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, et al: Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 2001;86:478-481.
28.
Wurzburger MI, Prelevic GM, Sonksen PH, Balint-Peric LA, Wheeler M: The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes. J Clin Endocrinol Metab 1993;77:267-272.
29.
Shishko PI, Dreval AV, Abugova IA, Zajarny IU, Goncharov VC: Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res Clin Pract 1994;25:1-12.
30.
Leung KC, Doyle N, Ballesteros M, Waters MJ, Ho KK: Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab 2000;85:4712-4720.
31.
Neggers SJ, Kopchick JJ, Jørgensen JO, van der Lely AJ: Hypothesis: extra-hepatic acromegaly: a new paradigm? Eur J Endocrinol 2011;164:11-16.
32.
Pokrajac A, Frystyk J, Flyvbjerg A, Trainer PJ: Pituitary-independent effect of octreotide on IGF1 generation. Eur J Endocrinol 2009;160:543-548.
33.
Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S: Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 2004;114:349-356.
34.
Hodish I, Barkan A: Long-term effects of pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab 2008;4:324-332.
35.
Beauregard C, Truong U, Hardy J, Serri O: Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003;58:86-91.
36.
Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW: Long-term treatment outcome in acromegaly. Growth Horm IGF Res 2003;13:185-192.
37.
Holdaway IM, Rajasoorya RC, Gamble GD: Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667-674.
38.
Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, et al: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-3426.
39.
Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, et al: Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 2008;93:3853-3859.
40.
Neggers SJ, Biermasz NR, van der Lely AJ: What is active acromegaly and which parameters do we have? Clin Endocrinol (Oxf) 2012;76:609-614.
41.
Hua SC, Yan YH, Chang TC: Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol 2006;155:831-837.
42.
Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F: Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005;90:2731-2739.
43.
Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, et al: Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 2004;89:5369-5376.
44.
Bonapart IE, van Domburg R, ten Have SM, de Herder WW, Erdman RA, Janssen JA, et al: The ‘bio-assay' quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. Eur J Endocrinol 2005;152:217-224.
45.
Webb SM, Prieto L, Badia X, Albareda M, Catala M, Gaztambide S, et al: Acromegaly Quality of Life Questionnaire (ACROQOL): a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 2002;57:251-258.
46.
Madsen M, Poulsen PL, Orskov H, Moller N, Jorgensen JO: Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J Clin Endocrinol Metab 2011;96:2405-2413.
47.
Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S: Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 2008;93:3515-3518.
48.
Maffei P, Martini C, Pagano C, Sicolo N, Corbetti F: Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant. Ann Intern Med 2006;145:310-312.
49.
Bernabeu I, Marazuela M, Lucas T, Loidi L, Alvarez-Escola C, Luque-Ramirez M, et al: Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome. J Clin Endocrinol Metab 2010;95:2147-2154.
50.
Madsen M, Krusenstjerna-Hafstrom T, Moller L, Christensen B, Vendelbo MH, Pedersen SB, et al: Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial. J Clin Endocrinol Metab 2012;97:1227-1235.
51.
Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prevost G, et al: Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 2014;99:1282-1290.
52.
Bevan JS: Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005;90:1856-1863.
53.
Marazuela M, Paniagua AE, Gahete MD, Lucas T, Alvarez-Escola C, Manzanares R, et al: Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. J Clin Endocrinol Metab 2011;96:E251-E259.
54.
de Herder WW: The history of acromegaly. Neuroendocrinology 2016;103:7-17.
55.
Schernthaner-Reiter MH, Trivellin G, Stratakis CA: MEN1, MEN4, and carney complex: pathology and molecular genetics. Neuroendocrinology 2016;103:18-31.
56.
Buchfelder M, Schlaffer S-M: Novel techniques in the surgical treatment of acromegaly: applications and efficacy. Neuroendocrinology 2016;103:32-41.
57.
Hannon MJ, Barkan AL, Drake WM: The role of radiotherapy in acromegaly. Neuroendocrinology 2016;103:42-49.
58.
Chanson P: Medical treatment of acromegaly with dopamine agonists or somatostatin analogs. Neuroendocrinology 2016;103:50-58.
59.
McCabe J, Ayuk J, Sherlock M: Treatment factors that influence mortality in acromegaly. Neuroendocrinology 2016;103:66-74.
60.
Powlson AS, Gurnell M: Cardiovascular disease and sleep-disordered breathing in acromegaly. Neuroendocrinology 2016;103:75-85.
61.
Claessen KMJA, Mazziotti G, Biermasz NR, Giustina A: Bone and joint disorders in acromegaly. Neuroendocrinology 2016;103:86-95.
62.
Dal J, List EO, Jørgensen JOL, Berryman DE: Glucose and fat metabolism in acromegaly: from mice models to patient care. Neuroendocrinology 2016;103:96-105.
63.
Webb SM, Badia X: Quality of life in acromegaly. Neuroendocrinology 2016;103:106-111.
© 2016 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.